Decorin-TGFβ Axis in Hepatic Fibrosis and Cirrhosis

Kornélia Baghy, Renato V. Iozzo, I. Kovalszky

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Hepatic fibrosis and cirrhosis are worldwide health care problems, especially in regions with a high rate of hepatitis infection. As these diseases affect a major part of the human population, the search for antifibrotic therapies has a high priority in medical research. Transforming growth factor β1 (TGF-β1) is one of the most powerful profibrotic cytokines. Thus, blocking TGF-β1 activity by natural inhibitors represents a valid and logical strategy to combat hepatic fibrosis. One of the natural inhibitors of TGF-β1 is decorin, a small leucine-rich proteoglycan that binds with high affinity to this cytokine and prevents its interaction with pro-fibrotic receptors. Recent evidence has shown that decorin has a protective role in liver fibrogenesis insofar as its genetic ablation in mice leads to enhanced matrix deposition, impaired matrix degradation, and "activation" of hepatic stellate cells, the main producers of fibrotic tissue. Moreover, TGF-β1 exerts a stronger effect when functional decorin is absent. These data provide robust genetic evidence for a direct role of endogenous decorin in preventing and retarding hepatic fibrosis. Thus, boosting the endogenous production of decorin or systemic delivery of recombinant decorin could represent an additional therapeutic modality against hepatic fibrosis.

Original languageEnglish
Pages (from-to)262-268
Number of pages7
JournalJournal of Histochemistry and Cytochemistry
Volume60
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Decorin
Liver Cirrhosis
Fibrosis
Transforming Growth Factors
Liver
Cytokines
Hepatic Stellate Cells
Hepatitis
Biomedical Research
Delivery of Health Care
Therapeutics
Infection
Population

Keywords

  • decorin
  • extracellular matrix
  • hepatic stellate cells
  • liver fibrosis
  • small leucine-rich proteoglycan
  • TGF-β1

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Decorin-TGFβ Axis in Hepatic Fibrosis and Cirrhosis. / Baghy, Kornélia; Iozzo, Renato V.; Kovalszky, I.

In: Journal of Histochemistry and Cytochemistry, Vol. 60, No. 4, 04.2012, p. 262-268.

Research output: Contribution to journalArticle

Baghy, Kornélia ; Iozzo, Renato V. ; Kovalszky, I. / Decorin-TGFβ Axis in Hepatic Fibrosis and Cirrhosis. In: Journal of Histochemistry and Cytochemistry. 2012 ; Vol. 60, No. 4. pp. 262-268.
@article{1e598878301e43a3bb6f77452b9bfedb,
title = "Decorin-TGFβ Axis in Hepatic Fibrosis and Cirrhosis",
abstract = "Hepatic fibrosis and cirrhosis are worldwide health care problems, especially in regions with a high rate of hepatitis infection. As these diseases affect a major part of the human population, the search for antifibrotic therapies has a high priority in medical research. Transforming growth factor β1 (TGF-β1) is one of the most powerful profibrotic cytokines. Thus, blocking TGF-β1 activity by natural inhibitors represents a valid and logical strategy to combat hepatic fibrosis. One of the natural inhibitors of TGF-β1 is decorin, a small leucine-rich proteoglycan that binds with high affinity to this cytokine and prevents its interaction with pro-fibrotic receptors. Recent evidence has shown that decorin has a protective role in liver fibrogenesis insofar as its genetic ablation in mice leads to enhanced matrix deposition, impaired matrix degradation, and {"}activation{"} of hepatic stellate cells, the main producers of fibrotic tissue. Moreover, TGF-β1 exerts a stronger effect when functional decorin is absent. These data provide robust genetic evidence for a direct role of endogenous decorin in preventing and retarding hepatic fibrosis. Thus, boosting the endogenous production of decorin or systemic delivery of recombinant decorin could represent an additional therapeutic modality against hepatic fibrosis.",
keywords = "decorin, extracellular matrix, hepatic stellate cells, liver fibrosis, small leucine-rich proteoglycan, TGF-β1",
author = "Korn{\'e}lia Baghy and Iozzo, {Renato V.} and I. Kovalszky",
year = "2012",
month = "4",
doi = "10.1369/0022155412438104",
language = "English",
volume = "60",
pages = "262--268",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "4",

}

TY - JOUR

T1 - Decorin-TGFβ Axis in Hepatic Fibrosis and Cirrhosis

AU - Baghy, Kornélia

AU - Iozzo, Renato V.

AU - Kovalszky, I.

PY - 2012/4

Y1 - 2012/4

N2 - Hepatic fibrosis and cirrhosis are worldwide health care problems, especially in regions with a high rate of hepatitis infection. As these diseases affect a major part of the human population, the search for antifibrotic therapies has a high priority in medical research. Transforming growth factor β1 (TGF-β1) is one of the most powerful profibrotic cytokines. Thus, blocking TGF-β1 activity by natural inhibitors represents a valid and logical strategy to combat hepatic fibrosis. One of the natural inhibitors of TGF-β1 is decorin, a small leucine-rich proteoglycan that binds with high affinity to this cytokine and prevents its interaction with pro-fibrotic receptors. Recent evidence has shown that decorin has a protective role in liver fibrogenesis insofar as its genetic ablation in mice leads to enhanced matrix deposition, impaired matrix degradation, and "activation" of hepatic stellate cells, the main producers of fibrotic tissue. Moreover, TGF-β1 exerts a stronger effect when functional decorin is absent. These data provide robust genetic evidence for a direct role of endogenous decorin in preventing and retarding hepatic fibrosis. Thus, boosting the endogenous production of decorin or systemic delivery of recombinant decorin could represent an additional therapeutic modality against hepatic fibrosis.

AB - Hepatic fibrosis and cirrhosis are worldwide health care problems, especially in regions with a high rate of hepatitis infection. As these diseases affect a major part of the human population, the search for antifibrotic therapies has a high priority in medical research. Transforming growth factor β1 (TGF-β1) is one of the most powerful profibrotic cytokines. Thus, blocking TGF-β1 activity by natural inhibitors represents a valid and logical strategy to combat hepatic fibrosis. One of the natural inhibitors of TGF-β1 is decorin, a small leucine-rich proteoglycan that binds with high affinity to this cytokine and prevents its interaction with pro-fibrotic receptors. Recent evidence has shown that decorin has a protective role in liver fibrogenesis insofar as its genetic ablation in mice leads to enhanced matrix deposition, impaired matrix degradation, and "activation" of hepatic stellate cells, the main producers of fibrotic tissue. Moreover, TGF-β1 exerts a stronger effect when functional decorin is absent. These data provide robust genetic evidence for a direct role of endogenous decorin in preventing and retarding hepatic fibrosis. Thus, boosting the endogenous production of decorin or systemic delivery of recombinant decorin could represent an additional therapeutic modality against hepatic fibrosis.

KW - decorin

KW - extracellular matrix

KW - hepatic stellate cells

KW - liver fibrosis

KW - small leucine-rich proteoglycan

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=84864796944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864796944&partnerID=8YFLogxK

U2 - 10.1369/0022155412438104

DO - 10.1369/0022155412438104

M3 - Article

C2 - 22260996

AN - SCOPUS:84864796944

VL - 60

SP - 262

EP - 268

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 4

ER -